FAES FARMA, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.38 EUR | +1.81% |
|
+6.12% | +6.96% |
| Apr. 26 | FAES FARMA : Q1 beat; full-year guidance re-affirmed |  |
| Feb. 27 | FAES FARMA : Q4 profitability exceeded expectations | |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,370 | 980.4 | 1,019 | 1,074 | 992.3 | 1,052 | - | - |
| Enterprise Value (EV) 1 | 1,324 | 905.1 | 969.7 | 1,045 | 992.3 | 1,062 | 987.6 | 1,005 |
| P/E ratio | 21.4 x | 14 x | 12.9 x | 12 x | - | 11.7 x | 11.4 x | 11.9 x |
| Yield | 3.36% | 4.87% | 5.75% | 4.42% | - | 4.59% | 4.66% | 2.76% |
| Capitalization / Revenue | 3.57 x | 2.38 x | 2.56 x | 2.45 x | 2.2 x | 2.21 x | 2.12 x | 2.11 x |
| EV / Revenue | 3.46 x | 2.2 x | 2.43 x | 2.38 x | 2.2 x | 2.23 x | 1.99 x | 2.01 x |
| EV / EBITDA | 14.5 x | 8.45 x | 8.48 x | 8.65 x | 8.12 x | 8.38 x | 7.45 x | 7.95 x |
| EV / FCF | 26.2 x | 17.2 x | 47.9 x | 241 x | - | 19.5 x | 12.5 x | 10.6 x |
| FCF Yield | 3.82% | 5.83% | 2.09% | 0.42% | - | 5.14% | 8.02% | 9.39% |
| Price to Book | - | - | 1.9 x | 1.79 x | - | 1.5 x | 1.41 x | 1.33 x |
| Nbr of stocks (in thousands) | 273,938 | 280,909 | 292,875 | 305,996 | 314,021 | 311,249 | - | - |
| Reference price 2 | 5.000 | 3.490 | 3.478 | 3.510 | 3.160 | 3.380 | 3.380 | 3.380 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/25/22 | 2/28/23 | 2/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 383.2 | 411.5 | 398.6 | 438.8 | 451.2 | 476.3 | 496.5 | 499.3 |
| EBITDA 1 | 91.51 | 107.1 | 114.4 | 120.8 | 122.2 | 126.7 | 132.5 | 126.4 |
| EBIT 1 | 74.86 | 86.77 | 94.28 | 101.5 | 102.8 | 106.5 | 110.8 | 104 |
| Operating Margin | 19.54% | 21.09% | 23.65% | 23.13% | 22.79% | 22.36% | 22.31% | 20.83% |
| Earnings before Tax (EBT) 1 | 74.18 | 84.88 | 93.99 | 101.4 | 102.9 | 109 | 114 | 113 |
| Net income 1 | 63.96 | 72.55 | 83.16 | 89.55 | 91.9 | 89.77 | 91.87 | 88.9 |
| Net margin | 16.69% | 17.63% | 20.86% | 20.41% | 20.37% | 18.85% | 18.5% | 17.8% |
| EPS 2 | 0.2340 | 0.2500 | 0.2700 | 0.2930 | - | 0.2900 | 0.2967 | 0.2833 |
| Free Cash Flow 1 | 50.61 | 52.77 | 20.23 | 4.34 | - | 54.55 | 79.25 | 94.35 |
| FCF margin | 13.21% | 12.82% | 5.08% | 0.99% | - | 11.45% | 15.96% | 18.9% |
| FCF Conversion (EBITDA) | 55.31% | 49.25% | 17.69% | 3.59% | - | 43.05% | 59.8% | 74.62% |
| FCF Conversion (Net income) | 79.13% | 72.73% | 24.33% | 4.85% | - | 60.77% | 86.27% | 106.13% |
| Dividend per Share 2 | 0.1680 | 0.1700 | 0.2000 | 0.1550 | - | 0.1550 | 0.1575 | 0.0933 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/25/22 | 2/28/23 | 2/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 201.3 | 192.2 | 77.68 | 116.2 | 114.8 | 231 | 121 | 118.4 | 117.8 | - | 125.8 |
| EBITDA | 66.99 | 63.12 | 19.29 | 35.92 | 35.04 | 70.95 | 29.68 | 37 | 34.25 | 71.41 | - |
| EBIT 1 | 55.86 | 55.27 | 11.04 | - | 30.26 | 61.86 | 24.39 | 32.55 | 29.39 | 61.94 | 25.47 |
| Operating Margin | 27.75% | 28.76% | 14.21% | - | 26.36% | 26.78% | 20.15% | 27.48% | 24.96% | - | 20.25% |
| Earnings before Tax (EBT) 1 | 55.09 | - | - | 31.79 | 30.44 | 62.23 | 24.2 | 32.58 | 29.65 | 62.23 | 25.37 |
| Net income 1 | 45.58 | 47.19 | 12 | 26.62 | 26.44 | 53.06 | 20.94 | 27.62 | 25.38 | 53 | 21.16 |
| Net margin | 22.64% | 24.55% | 15.45% | 22.91% | 23.03% | 22.97% | 17.3% | 23.31% | 21.56% | - | 16.82% |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/29/20 | 7/28/21 | 2/25/22 | 4/29/22 | 7/28/22 | 7/28/22 | 10/27/22 | 5/2/23 | 7/28/23 | 7/28/23 | 10/25/23 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 9.8 | - | - |
| Net Cash position 1 | 45.4 | 75.2 | 48.9 | 29.4 | - | - | 64.5 | 47.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 0.0773 x | - | - |
| Free Cash Flow 1 | 50.6 | 52.8 | 20.2 | 4.34 | - | 54.6 | 79.3 | 94.4 |
| ROE (net income / shareholders' equity) | 16.6% | 16.4% | 16.5% | 15.7% | - | 13% | 12.5% | 11.4% |
| ROA (Net income/ Total Assets) | - | - | - | 13.1% | - | 10.6% | 10.4% | 9.8% |
| Assets 1 | - | - | - | 683.7 | - | 846.9 | 883.3 | 907.1 |
| Book Value Per Share 2 | - | - | 1.830 | 1.960 | - | 2.250 | 2.400 | 2.540 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 21.4 | 25.7 | 59.4 | 102 | - | 43.9 | 27 | 23 |
| Capex / Sales | 5.59% | 6.25% | 14.91% | 23.35% | - | 9.22% | 5.44% | 4.61% |
| Announcement Date | 2/28/20 | 2/26/21 | 2/25/22 | 2/28/23 | 2/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
3.38
EUR
Average target price
3.708
EUR
Spread / Average Target
+9.69%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.96% | 1.12B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- FAE Stock
- Financials Faes Farma, S.A.
